ClinDatrix: Specialized Clinical Trials for Hematology
Since our founding in 2002, ClinDatrix has amassed over two decades of experience in conducting clinical trials across all phases (I–III). We have completed studies in hematologic malignancies, sickle cell anemia, GVHD in bone marrow transplants, and sickle beta-thalassemia. Our expertise in managing complex study protocols, designing specialized electronic data capture (EDC) systems, and streamlining trial logistics makes ClinDatrix a trusted partner in hematology research.
We excel at developing custom EDC databases tailored to intricate protocols for hematologic diseases. With a deep understanding of electronic case report form (eCRF) design, protocol refinement, and clinical trial logistics, ClinDatrix ensures sponsors have the tools they need to succeed in their studies.
Key Highlights of ClinDatrix Hematology Expertise
- Agility in Study Management: We deploy study databases on our secure servers within 5 weeks—well ahead of the industry standard of 12 weeks—and implement protocol adjustments within 1–2 days, ensuring quick adaptability to evolving study requirements.
- Regulatory and Compliance Excellence: Our commitment to regulatory rigor ensures full compliance with ethical and legal standards, providing sponsors with confidence in every phase of their hematology trials.
- Precision and Operational Excellence: We deliver end-to-end support from protocol development to data analysis, empowering sponsors to meet their study goals accurately and efficiently.
Contact ClinDatrix today to learn how our specialized hematology clinical trial services can support your research initiatives and drive advancements in treating hematologic conditions.
ClinDatrix Studies
Service Codes
- BI = Biostatistics
- CL = Clinical
- DM = Data Management
- FS = Full Service
- MS = Medical Safety
- MW = Medical Writing
- RA = Regulatory Affairs
| Phase | Indication | Services | Sites | Patients |
|---|---|---|---|---|
| 2 | Sickle-Cell Anemia, Sickle Beta-Thalassemia | BI, CL, DM | 5 | 80 |
| 2 | Sickle-Cell Anemia – Exercise Study | BI, CL, DM | 1 | 15 |
| 2 | Hematologic Malignancies | DM | 4 | 90 |
| 3 | Sickle-Cell Anemia, Sickle Beta-Thalassemia | FS | 31 | 23 |